E-QURE Corp Signs Second Distribution Agreement in Israel
PR Newswire - Mon Aug 03, 8:00AM CDT
E-QURE Corp. (OTCQB: EQUR), a Delaware Corporate engaged in the commercialization of its Bio-electrical Signal Therapy device ("BST Device"
E-QURE Corp. Presentation Now Available for On-Demand Viewing
PR Newswire - Tue Jul 14, 7:11AM CDT
E-QURE Corp. (OTCQB: EQUR), today announced that the July 9 presentation from Chairman Ron Weissberg, is now available for on-demand viewing at VirtualInvestorConferences.com.
Nasdaq and OTC Markets Companies to Present Online to Investors on July 9
PR Newswire - Tue Jul 07, 7:00AM CDT
PR Newswire and BetterInvesting (NAIC) today announced the agenda for the upcoming VirtualInvestorConferences.com, the evergreen online investor conference series. Individual investors, institutional investors, advisors and analysts are invited. The show opens at 9:00 AM ET, with the first live webcast at 9:15 AM ET.
PSEC: 8.42 (-0.04)
E-QURE Corp to Webcast, Live, at VirtualInvestorConferences.com July 9
PR Newswire - Mon Jul 06, 7:38AM CDT
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com
E-QURE Corp Signs First Distribution Agreement in Argentina
PR Newswire - Wed Jun 10, 5:39AM CDT
E-QURE Corp. (OTCQB: EQUR), a Delaware Corporate engaged in the commercialization of its Bio-electrical Signal Therapy device ("BST Device"
Zacks Investment Small Cap Research Issues Quarterly Update on E-QURE
PR Newswire - Wed May 27, 10:23AM CDT
E-QURE, Corp. (OTCQB: EQUR), a Delaware corporation engaged in the development and commercialization of its Bio-electrical Signal Therapy device ("BST Device"
E-QURE Corp. Issues 2014 - 2015 Update to Shareholders
PR Newswire - Tue May 05, 8:00AM CDT
E-QURE (Electric Quick Ulcer Remedy) Corp. (OTCQB: EQUR); ("E-QURE" or the "Company"
E-QURE has established a Scientific Advisory Board appointing Dr. Ben-Zion Weiner and Prof. Avi Ohry
ACCESSWIRE - Sun Apr 12, 11:58AM CDT
The Wound Healing Medical Device Company Nominated Two Prominent, Well Experiences Scientists, To Guide The Company In Its Coming Clinical Trial And Industry Recognition
TEVA: 52.99 (-0.06)